Does myeloperoxidase promote LDL oxidation and kidney microvascular dysfunction?

Myeloperoxidase (MPO) serves as a critical enzymatic link between systemic inflammation, lipid oxidation, and the progressive decline of renal microvascular function. In the aging vasculature, particularly in patients over 70, elevated MPO activity acts as a potent driver of oxidative stress and endothelial impairment.

Mechanistic pathways of MPO damage

MPO, a heme-containing enzyme released primarily by activated neutrophils, orchestrates vascular damage through several distinct pathways:

• LDL Oxidation: MPO directly modifies low-density lipoprotein (LDL) via chlorination and nitration of its ApoB-100 protein. This produces myeloperoxidase-oxidized LDL (Mox-LDL), a highly atherogenic particle that facilitates foam cell formation and binds to the LOX-1 scavenger receptor on endothelial cells.
• Nitric Oxide Depletion: MPO acts as a "sink" for nitric oxide (NO), consuming it as a substrate. This reduction in NO bioavailability directly impairs vasodilation and disrupts the vascular barrier, a process independently associated with reduced flow-mediated dilation (FMD) in clinical cohorts.

Impact on renal microvascular health

The kidney is uniquely susceptible to the downstream effects of MPO-driven endothelial dysfunction due to its dense, specialized microvasculature.

• Microvascular Rarefaction: Endothelial dysfunction leads to a structural loss of capillary density (rarefaction). This reduces renal perfusion and creates a state of chronic hypoxia, which triggers fibrotic cascades and macrophage infiltration.
• Filtration Impairment: The resulting increase in intrarenal vascular resistance—often measured via the renal resistive index (RI)—is a strong predictor of clinical decline. Research indicates that an elevated RI significantly increases the risk of doubling serum creatinine or progressing to dialysis (Hazard Ratio 4.88).

Bottom line

Myeloperoxidase is a validated marker and mediator of vascular oxidative stress that promotes LDL oxidation and endothelial dysfunction. In the kidneys, these processes manifest as impaired microvascular blood flow and structural rarefaction, directly contributing to the progression of chronic kidney disease and loss of filtration capacity.